Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Hepatitis C immune globulin - Biotest Pharmaceuticals

Drug Profile

Hepatitis C immune globulin - Biotest Pharmaceuticals

Alternative Names: Boca HBVIg - Biotest; Civacir; HCVIG; Hepatitis C Immune Globulin Intravenous (Human) 5% - Biotest Pharmaceuticals

Latest Information Update: 14 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Nabi Biopharmaceuticals
  • Developer Biotest Pharmaceuticals; Kedrion
  • Class Antivirals; Immunoglobulins
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hepatitis C
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Hepatitis C

Most Recent Events

  • 03 Oct 2019 Prometic Life Sciences is now called Liminal BioSciences
  • 01 Aug 2018 Biotest Pharmaceuticals has been acquired by Grifols Shared Services North America
  • 05 May 2017 Discontinued - Phase-II for Hepatitis C (Prevention of relapse) in European Union (IV) before May 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top